CytomX Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Great. So good afternoon, and my name is Peter Lawson. I'm one of the biotech analysts at Barclays. Welcome to Barclays Global Healthcare Conference. I just want to thank everybody for taking the time out of their day. And if institutional investors have questions, do ping me, [email protected] or you can ping on Bloomberg. It gives me great pleasure today to introduce the CEO from CytomX, so Sean McCarthy. And just with that, Sean, just your kind of view on the differentiation of CytomX in this kind of broad landscape of oncology companies and various assets being developed.
Yes. Great. Thanks, Peter. Thanks for having us on today as part of the conference. Pleasure to be here. So I think one of the things that CytomX -- we've always had going for us is our intrinsic differentiation. So we began life as a company that set out to reinvent therapeutic antibodies about a decade ago, actually. And the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
